Identifying Biological Markers for Severe Depression

Stanford University3 sites in 1 country210 target enrollmentJuly 2013

ConditionsMajor Depressive Disorder

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Major Depressive Disorder
Sponsor: Stanford University
Enrollment: 210
Locations: 3
Primary Endpoint: Genetics
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to investigate the biological components of major depression. The investigators are particularity interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than mild depression or healthy controls) and how it contributes to clinical symptoms, especially suicidal ideation/behavior and psychosis.

Registry

clinicaltrials.gov

Start Date

July 2013

End Date

August 2020

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Stanford University

Responsible Party

Principal Investigator

Alan Schatzberg

Principle Investigator

Stanford University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Genetics

Time Frame: 1 year

Blood will be drawn for gene expression, which includes genetics and metallothionein assessments. Blood will also be drawn for later assay of immune function/measures and neurotophins, and for future studies.